Evert Schimmelpennink - LENZ Therapeutics CEO and Presidentident
| LENZ Stock | 37.30 1.05 2.90% |
CEO
Evert Schimmelpennink is CEO and Presidentident of LENZ Therapeutics
| Age | 52 |
| Address | 445 Marine View Avenue, Del Mar, CA, United States, 92014 |
| Phone | (858) 925-7000 |
| Web | https://www.lenz-tx.com |
Evert Schimmelpennink Latest Insider Activity
Tracking and analyzing the buying and selling activities of Evert Schimmelpennink against LENZ Therapeutics stock is an integral part of due diligence when investing in LENZ Therapeutics. Evert Schimmelpennink insider activity provides valuable insight into whether LENZ Therapeutics is net buyers or sellers over its current business cycle. Note, LENZ Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell LENZ Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Evert Schimmelpennink over three months ago Acquisition by Evert Schimmelpennink of 45000 shares of LENZ Therapeutics at 1.04 subject to Rule 16b-3 | ||
Evert Schimmelpennink over six months ago Acquisition by Evert Schimmelpennink of 82723 shares of LENZ Therapeutics at 5.05 subject to Rule 16b-3 |
LENZ Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7717) % which means that it has lost $0.7717 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5761) %, meaning that it created substantial loss on money invested by shareholders. LENZ Therapeutics' management efficiency ratios could be used to measure how well LENZ Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2024. Return On Capital Employed is likely to rise to -0.38 in 2024. At this time, LENZ Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 190.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 413.2 K in 2024.Similar Executives
| Found 7 records | CEO Age | ||
| Joseph MBA | Milestone Pharmaceuticals | 56 | |
| Mark Manfredi | Ikena Oncology | 53 | |
| Shaun Bagai | RenovoRx | 47 | |
| LLM JD | Tempest Therapeutics | 54 | |
| John Tucker | Scpharmaceuticals | 61 | |
| Eric MBA | Seres Therapeutics | 48 | |
| BAO BCh | Eliem Therapeutics | 48 | |
Management Performance
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.77 |
LENZ Therapeutics Leadership Team
Elected by the shareholders, the LENZ Therapeutics' board of directors comprises two types of representatives: LENZ Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LENZ. The board's role is to monitor LENZ Therapeutics' management team and ensure that shareholders' interests are well served. LENZ Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LENZ Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Evert Schimmelpennink, CEO and Presidentident | ||
| Marvin Garrett, Senior Quality | ||
| Breianna Bowen, Vice Resources | ||
| Gerald Horn, Senior Founder | ||
| James McCollum, CoFounder Director | ||
| David Murphy, Senior Development | ||
| Daniel CPA, Chief Officer | ||
| Marc MD, Chief Officer | ||
| Shawn Olsson, Chief Officer | ||
| Domenick Porfidia, Vice Sales |
LENZ Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LENZ Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.77 | ||||
| Current Valuation | 406.07 M | ||||
| Shares Outstanding | 27.47 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 86.06 % | ||||
| Number Of Shares Shorted | 2.18 M | ||||
| Price To Book | 3.11 X | ||||
| EBITDA | (122.24 M) | ||||
| Net Income | (124.65 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.